U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Oakdell Pharmacy, Inc - Close Out Letter 12/21/17
  1. Warning Letters

CLOSEOUT LETTER

Oakdell Pharmacy, Inc


Recipient:
Oakdell Pharmacy, Inc


United States

Issuing Office:

United States


 

  

Black HHS-Blue FDA Logo

 

Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204 

 
 

December 21, 2017

Mr. John J. Carson, R.Ph.
Chief-of-Staff
Oakdell Pharmacy, LLC
7220 Louis Pasteur Drive, Suite 176
San Antonio, TX 78229-4535

Mr. Carson:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [Ref: 2014-DAL-WL-04 dated May 27, 2014]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have additional questions, please contact Thao Ta, Compliance Officer, at 214-253-5217, or by email at Thao.Ta@fda.hhs.gov.

Sincerely,
/S/

John Diehl
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II